Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 134.87B +10.3% |
| Revenue (ttm) | 27.03B +22.3% |
| Net Income | 5.16B -37.9% |
| EPS | 82.78 -36.8% |
| Shares Out | 59.75M |
| PE Ratio | 27.26 |
| Forward PE | 23.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,414 |
| Open | 2,323.00 |
| Previous Close | 2,257.00 |
| Day's Range | 2,310.00 - 2,370.00 |
| 52-Week Range | 1,512.00 - 2,370.00 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 2,453.79 (+5.68%) |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price target is kr 2,454, which is an increase of 5.68% from the latest price.
News
Genmab price target raised to $54 from $45 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $54 from $45 and keeps a Buy rating on the shares. The stock remains the analyst’s top…
Genmab (GMAB) Reports Encouraging Phase 1/2 RAINFOL-01 Results in Platinum-Resistant Ovarian Cancer
Genmab (GMAB) Reports Encouraging Phase 1/2 RAINFOL-01 Results in Platinum-Resistant Ovarian Cancer
Genmab announces Rina-S Phase 2 RAINFOL-1 trial results
Genmab (GMAB) announced results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan demonstrated that among 109 treated patients with platinum-resistant ovarian cancer, PROC,...
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
(RTTNews) - Genmab A/S (GMAB) reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating investigational antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with ...
Genmab A/S: Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Treatment with Rina-S 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resist...
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of...
Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoi...
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational fola...
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Market...
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
Genmab A/S NASDAQ: GMAB expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs that the company views as potential first-in-class opportunities, accor...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants ...
Genmab Transcript: Bank of America Global Healthcare Conference
Three late-stage oncology assets are set for pivotal phase III readouts in Q4 2026, with broad development programs and potential first-in-class positioning. Commercial launches for Rina-S, petosemtamab, and EPKINLY are targeted for 2027, supported by robust infrastructure and a strong royalty base.
Genmab Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Multiple late-stage assets are advancing, with six new phase III trials and strong financial growth. Petosemtamab and EPKINLY are poised for major data readouts in Q4, potentially setting new standards in head and neck, colorectal, and B-cell cancers.
Genmab A/S (CPH:GEN) -- Oncology Innovation and Growth | Artisan International Small-Mid Fund ...
Genmab A/S (CPH:GEN) -- Oncology Innovation and Growth | Artisan International Small-Mid Fund Q3 2026
Genmab Transcript: Wells Fargo 21st Annual Healthcare Conference
Three major phase III readouts are expected next quarter, including pivotal data for epcoritamab in first-line DLBCL, petosemtamab in head and neck cancer, and Rina-S in PROC. Epcoritamab and petosemtamab are positioned for significant commercial opportunities, with Rina-S aiming for best-in-class efficacy and broad indication expansion.
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The incr...
Notice to Convene an Extraordinary General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary Gene...
Genmab price target raised to DKK 2,500 from DKK 2,250 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Genmab (GMAB) to DKK 2,500 from DKK 2,250 and keeps a Buy rating on the shares. Published first on…
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor con...
Genmab Slides: Investor presentation
Genmab has posted slides in relation to its latest quarterly earnings report, which was published on August 22, 2026.
Genmab price target raised to $35 from $33 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $35 from $33 and keeps an Equal Weight rating on the shares.
Genmab price target raised to $42 from $40 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $42 from $40 and keeps a Buy rating on the shares after the company reported “robust” Q2…
Genmab A/S Q2 Earnings Call Highlights
Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader portf...
Genmab Earnings Call Transcript: Q2 2026
Revenue grew 25% year-over-year, driven by strong sales of EPKINLY and DARZALEX, with adjusted operating profit up 18%. Multiple late-stage data readouts are expected in Q4 2026 and early 2027, supporting a raised full-year revenue outlook and continued investment in pipeline expansion.
Genmab Quarterly report: Q2 2026
Genmab has published its Q2 2026 quarterly earnings report on August 6, 2026.